Curated CRC research — accessible, accurate, actionable

The CRC Digest

Tuesday, August 25, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ◆ TRIAL DATA

  Ifebemtinib plus garsorasib shows activity in KRAS G12C-mutated metastatic colorectal cancer

  A phase 1b/2 trial tested the combination of ifebemtinib (a focal adhesion kinase inhibitor) with garsorasib (a KRAS G12C inhibitor) in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The recommended phase 2 dose was established as ifebemtinib 100 mg once daily plus garsorasib 600 mg twice daily. (Lancet Oncology)

• ◆ TRIAL DATA

  Dual checkpoint blockade compared to single-agent PD-1 in MSI-H metastatic colorectal cancer

  A study examined dual CTLA-4/PD-1 blockade versus anti–PD-1 alone in MSI-H metastatic colorectal cancer, reporting early survival benefit and exploratory clinical predictors. (Clinical Colorectal Cancer)

• ▸ TREATMENT

  HIPEC combined with surgery and systemic therapy may improve outcomes in peritoneal metastases

  An updated meta-analysis of 12 studies (including 2 randomized controlled trials) encompassing more than 2,700 patients found that hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery and systemic therapy improved progression-free survival and overall survival in colorectal cancer patients with peritoneal metastases. (Oncology)

• ▪ SCREENING

  New model suggests accelerated colorectal carcinogenesis may limit screening effectiveness

  Researchers propose an exposure-driven accelerated carcinogenesis model to explain rising early-onset CRC, increasing distal and rectal tumors, and post-colonoscopy CRC despite high-quality screening, suggesting that current slowly progressive models may not fully capture emerging CRC patterns. (Gut)

• ♥ LIVING WITH CRC

  Longitudinal toxicity analysis reveals chronic burden of cetuximab in metastatic colorectal cancer

  A pooled analysis of 1,302 patients from the ARCAD database applied a longitudinal toxicity framework to compare chemotherapy with or without cetuximab, finding that traditional single worst-grade reporting may underrepresent chronic or recurrent toxicity burden. (Journal of the National Cancer Institute)

These findings reflect ongoing efforts to personalize treatment, improve early detection, and better understand the burden of therapy in colorectal cancer care.